TP53 and neoplasm: These assays also demonstrate that while TP53 p.Arg181Cys loses some tumor suppressor functions, it does not cause additional oncogenic gain of function (GOF) which is typical to TP53 variant ‘hotspots’ associated with classical LFS [47–49].